Biogen Analyst Price Targets - Benzinga

SPY774.46+0.07%QQQ747.75+0.02%BTC/USD82,110.00+0.51%DIA511.79+0.03%GLD379.46+0.22%TLT77.66−0.27%

Biogen Inc

BIIBNASDAQ

Trade with Public

Trade with Public

$218.43

-3.72-1.67%

Last update: Oct 8, 4:00 PM

$218.43

-3.72-1.67%

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Biogen Analyst Price Targets

Wall Street analyst price targets and consensus rating for Biogen (BIIB).

Price Target Range — 7 Quarters

Analyst Consensus — 25 Analysts

18Buy

7Hold

Consensus RatingBuy# Analysts25Avg. Consensus PT$222Upside to Avg. PT+1.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2026	RBC Capital	Brian Abrahams	PT Cut	Outperform	$260→$256
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Reduce	$165→$175
Sep 3, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$225→$245
Aug 25, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$240→$260
Aug 13, 2026	Wolfe Research	Alexandria Hammond	Upgrade	Peer Perform→Outperform	$300
Aug 4, 2026	Mizuho	Salim Syed	PT Raise	Outperform	$221→$241
Aug 3, 2026	Citigroup	Geoff Meacham	PT Raise	Neutral	$200→$215
Jul 30, 2026	UBS	Michael Yee	PT Raise	Buy	$225→$240
Jul 30, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$237→$251
Jul 30, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Equal-Weight	$222→$231
Jul 30, 2026	RBC Capital	Brian Abrahams	PT Cut	Outperform	$242→$240
Jul 30, 2026	Canaccord Genuity	Sumant Kulkarni	PT Raise	Buy	$245→$248
Jul 30, 2026	TD Cowen	Phil Nadeau	PT Raise	Buy	$215→$225
Jul 30, 2026	Wedbush	Laura Chico	PT Raise	Neutral	$201→$215
Jul 29, 2026	Barclays	Emily Field	PT Raise	Equal-Weight	$185→$200
Jul 21, 2026	Guggenheim	Brad Canino	PT Raise	Buy	$260→$280
Jul 21, 2026	B of A Securities	Jason Zemansky	PT Cut	Neutral	$217→$215
Jul 13, 2026	Truist Securities	Danielle Brill	Upgrade	Hold→Buy	$190→$235
Jul 8, 2026	Morgan Stanley	Matthew Harrison	PT Cut	Equal-Weight	$224→$222
Jul 7, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$227→$242

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $256

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $260 to $256.

Benzinga Newsdesk

PRO
HSBC Maintains Reduce on Biogen, Raises Price Target to $175

HSBC analyst Rajesh Kumar maintains Biogen (NASDAQ:BIIB) with a Reduce and raises the price target from $165 to $175.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $245

Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $225 to $245.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Biogen, Raises Price Target to $260

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $240 to $260.

Benzinga Newsdesk

PRO
Wolfe Research Upgrades Biogen to Outperform, Announces $300 Price Target

Wolfe Research analyst Alexandria Hammond upgrades Biogen (NASDAQ:BIIB) from Peer Perform to Outperform and announces $300 price target.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Biogen, Raises Price Target to $241

Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $221 to $241.

Benzinga Newsdesk